What is extraskeletal osteosarcoma?
Extraskeletal osteosarcoma is a rare soft tissue cancer whose cells make bone-like material, even though the tumour is not attached to a bone. It usually grows deep in the muscles of the thigh, buttock, shoulder or back, and occasionally in organs such as the breast or bladder.
It is classed as a soft tissue sarcoma. Sarcomas are cancers of the body’s connective tissues, such as muscle, fat, nerves and bone. Only around 1-2% of soft tissue sarcomas are of this type.
The disease mostly affects older adults, usually in their 50s and 60s. It is an aggressive cancer: around one in five people already have spread to other organs when it is found, and about half of those treated for localised disease have a recurrence (Longhi et al., 2017; Heng et al., 2020).
How it differs from osteosarcoma of bone
Most osteosarcomas start inside a bone, as described on our page on osteosarcoma. Extraskeletal osteosarcoma makes the same kind of bone material, but it behaves differently.
| Feature | Osteosarcoma of bone | Extraskeletal osteosarcoma |
|---|---|---|
| Where it starts | Inside a bone, often near the knee or shoulder | In soft tissue, away from bone |
| Typical age | Children, teenagers and young adults | Mostly adults over 40 |
| Link to radiotherapy | Uncommon | Seen in a minority |
| Standard chemotherapy | Well established | Role debated |
| Response to chemotherapy | Often good | Less predictable |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade soft tissue sarcoma that forms bone material |
| How common | Very rare |
| Typical age | Usually 50-70 years; rare in children |
| Common sites | Deep soft tissue of the thigh, buttock, shoulder and back |
| Risk factors | Previous radiotherapy in some; usually no cause found |
| Main treatment | Wide surgical removal |
| Other treatments | Radiotherapy; chemotherapy in selected patients |
| Common spread | Lungs, followed by lymph nodes, bone and liver |
| Outlook | About half alive at five years |
2. Types
By microscopic pattern
| Subtype | Description |
|---|---|
| Osteoblastic | Mostly bone-forming cells |
| Chondroblastic | Contains cartilage-like areas |
| Fibroblastic | Mostly spindle cells with bone material |
| Telangiectatic | Blood-filled spaces |
| Small cell | Small round cells; rare |
| Well-differentiated | Low-grade; very rare at this site |
By origin
| Origin | Notes |
|---|---|
| Primary (de novo) | Most cases; no known cause |
| After radiotherapy | Arises in an area treated with radiation years earlier |
| In other organs | Rare cases in the breast, bladder, lung or other organs |
3. Causes and risk factors
| Factor | Notes |
|---|---|
| Age | Mostly older adults |
| Sex | Both men and women are affected |
| Previous radiotherapy | Can develop many years later in the treated area |
| Trauma | Often recalled, but no proven cause |
| Inherited syndromes | Li-Fraumeni syndrome raises sarcoma risk in general |
| Genetic changes in the tumour | Complex changes, often involving TP53, RB1 and CDKN2A |
Why does it occur in older adults?
Osteosarcoma of bone usually appears during the growth spurt, when bones are developing quickly. Extraskeletal osteosarcoma has no link to growth and instead seems to follow the pattern of other soft tissue sarcomas, which become more common with age. Researchers think it arises from primitive connective tissue cells that are able to make bone, but the exact cell of origin is unknown.
4. How does it look
On scans
| Scan | Typical findings |
|---|---|
| X-ray | A soft tissue mass with patchy or cloud-like calcification, not attached to bone |
| CT | Shows mineralised areas, often denser in the centre of the mass |
| MRI | Deep, mixed-signal mass, sometimes with bleeding or dead tissue |
| PET-CT | Helps detect spread |
A review of imaging noted that the calcified mass can be confused with myositis ossificans, a harmless bone-forming reaction in muscle after injury (Hesni et al., 2023). In myositis ossificans, bone forms first at the edge of the lesion, while in extraskeletal osteosarcoma it is often more central.
Under the microscope
| Feature | Description |
|---|---|
| Malignant cells | Large, irregular cells with abnormal nuclei |
| Osteoid | Lace-like bone matrix made directly by the cancer cells |
| Cartilage | Present in some tumours |
| Mitoses | Frequent, showing rapid division |
| Bone attachment | Absent, which separates it from osteosarcoma of bone |
Size and location
Most tumours are deep, below the fascia that covers the muscles. In a 370-patient study of localised disease, eight in ten were deep tumours (Heng et al., 2020). They are often 5-10 cm or more when found, because deep lumps can grow unnoticed.
5. Symptoms
Common symptoms
- A growing lump, usually in the thigh, buttock or shoulder
- Pain or tenderness in some patients
- Swelling of the affected limb
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Limp or reduced movement | Large tumour near a joint |
| Numbness or tingling | Pressure on a nerve |
| Leg swelling | Pressure on veins or lymph vessels |
| Cough or breathlessness | Spread to the lungs |
| Weight loss and tiredness | Advanced disease |
Why diagnosis is often delayed
Deep lumps in the thigh or buttock may not be visible, and they are often painless at first. Many people put them down to a pulled muscle or a bruise. By the time a scan is done, the tumour may already be large.
When to seek medical advice
Lumps that are larger than 5 cm, deep, growing or painful should be checked promptly with a scan. These are the warning signs used in sarcoma referral guidelines.
6. Diagnosis
| Step | What is done |
|---|---|
| Examination | Size, depth and mobility of the lump |
| Ultrasound | First test for many soft tissue lumps |
| MRI | Detailed image of the mass |
| CT | Shows calcification; CT of the chest checks the lungs |
| Core needle biopsy | Taken at a sarcoma centre along a track the surgeon can remove |
| Pathology review | Specialist sarcoma pathologist |
| PET-CT or bone scan | Staging in some patients |
Staging
Extraskeletal osteosarcoma is staged with the soft tissue sarcoma TNM system. All of these tumours are treated as high grade.
| Stage | Simplified meaning |
|---|---|
| Stage II | High-grade tumour up to 5 cm, no spread |
| Stage III | High-grade tumour larger than 5 cm, or spread to nearby nodes |
| Stage IV | Distant spread |
In the European study of 266 patients, about 19% had metastases at diagnosis (Longhi et al., 2017).
7. Treatment
Treatment should take place at a specialist sarcoma centre.
Surgery
| Aspect | Details |
|---|---|
| Aim | Remove the tumour with a margin of healthy tissue |
| Limb-sparing surgery | Possible in most patients |
| Amputation | Rarely needed |
| Reconstruction | Flaps or grafts if large areas are removed |
Almost all patients with localised disease in the European study had surgery, and clear margins were achieved in about seven in ten (Longhi et al., 2017).
Radiotherapy
| Timing | Purpose |
|---|---|
| Before surgery | Shrinks the tumour and may make surgery easier |
| After surgery | Lowers the risk of regrowth, especially with close margins |
| For symptom relief | Painful metastases |
In a large international study, radiotherapy was linked to a lower rate of local recurrence, though not to longer survival (Heng et al., 2020).
Chemotherapy
The role of chemotherapy is debated. Studies give different answers.
| Study | Main finding |
|---|---|
| European, 266 patients | Chemotherapy linked to better survival, with a trend favouring osteosarcoma-type regimens containing doxorubicin, ifosfamide and cisplatin (Longhi et al., 2017) |
| International, 370 patients | Chemotherapy did not lower the risk of distant spread or improve survival (Heng et al., 2020) |
| Mayo Clinic, 43 patients | Regimens including platinum were linked to much longer survival (Paludo et al., 2018) |
Many teams now discuss chemotherapy case by case, considering the patient’s age, fitness and tumour size. Osteosarcoma-type regimens are often preferred when chemotherapy is used.
Why do studies disagree about chemotherapy?
All the available studies look back at patients treated over several decades, at many centres and with different drugs. Patients who received chemotherapy were often younger and fitter, which can make the treatment look more effective than it really is. No randomised trial has compared chemotherapy with no chemotherapy in this disease. A shared decision with your sarcoma oncologist, weighing likely benefit against side effects, is therefore important.
Treatment of advanced disease
| Situation | Options |
|---|---|
| A few lung nodules | Surgical removal or stereotactic radiotherapy |
| Widespread disease | Chemotherapy, such as doxorubicin-based or cisplatin-based regimens |
| Clinical trials | Recommended where available |
| Symptom control | Palliative radiotherapy and supportive care |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Wound healing problems, weakness, stiffness |
| Radiotherapy | Skin reactions, wound complications if given before surgery, fibrosis, limb swelling |
| Doxorubicin | Hair loss, low blood counts, heart effects |
| Cisplatin | Hearing loss, kidney effects, sickness, numbness |
| Ifosfamide | Kidney and bladder effects, confusion |
8. Outlook (prognosis)
| Study | Five-year survival |
|---|---|
| European, all 266 patients | About 47% |
| European, metastatic at diagnosis | About 27% |
| International, localised disease | About 56% |
Factors that affect the outlook
| Factor | Effect |
|---|---|
| Tumour size | Smaller tumours do better |
| Age | Patients aged 40 or under did better in the European study |
| Margins | Clear margins lower the risk of local recurrence |
| Metastases at diagnosis | Poorer outlook |
In the international study, almost half of patients had a recurrence, most often as distant spread to the lungs (Heng et al., 2020). Local regrowth was less common.
9. Follow-up
| Period | Typical checks |
|---|---|
| Years 1-3 | Clinic visit and chest imaging every 3-4 months; MRI of the site as advised |
| Years 4-5 | Every 6 months |
| After 5 years | Yearly |
10. Living with extraskeletal osteosarcoma
- Follow your physiotherapy programme to rebuild strength
- Report new lumps, cough or breathlessness without delay
- Look after the treated skin if you had radiotherapy
- Keep active within your limits
- Ask for hearing and heart checks if you had cisplatin or doxorubicin
- Seek support from sarcoma charities
Recovery after surgery
| Period | What to expect |
|---|---|
| First days | Pain control, wound care, getting out of bed |
| 2-6 weeks | Wound healing; gentle exercises |
| 6-12 weeks | Increasing activity and strength work |
| 3-6 months | Return to most usual activities |
Coping with a rare cancer
Being diagnosed with a cancer that few people have heard of can feel lonely. Sarcoma specialist nurses can explain what to expect, coordinate your appointments and help with practical problems such as work, travel and money. National sarcoma charities run helplines and online groups where you can talk with others who have had similar treatment.
Some people find it helpful to bring a family member or friend to appointments, to write down questions in advance and to ask for written summaries of what was discussed.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it bone cancer? | It makes bone material but starts in soft tissue, so it is treated as a soft tissue sarcoma |
| Did an injury cause it? | No; an injury may draw attention to a lump that was already there |
| Will I need chemotherapy? | Possibly; the decision depends on your age, fitness and tumour |
| Can it be cured? | Yes, many people with localised disease are cured with surgery and radiotherapy |
| Will my limb work normally? | Most people regain good function, though some weakness may remain |
| Should I avoid exercise? | No; regular, gentle activity helps recovery, but ask about any restrictions after surgery |
| How quickly does it grow? | Usually over weeks to months, which is why a growing lump needs prompt checks |
| Can radiotherapy cause it? | Rarely, many years after treatment for another cancer |
12. Questions to ask your care team
- Is my tumour attached to bone, or entirely in soft tissue?
- Has it spread to my lungs or elsewhere?
- Will you give radiotherapy before or after surgery?
- Do you recommend chemotherapy for me, and which kind?
- What will my recovery look like?
- How often will I have scans?
- Is there a clinical trial for me?
- Who is my key worker in the sarcoma team?
- What symptoms should make me call you between visits?
Resources
- Heng, M. et al. (2020) ‘The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma’, European Journal of Cancer, 125, pp. 130-141.
- Hesni, S. et al. (2023) ‘Extra-skeletal osteosarcoma: a review’, Skeletal Radiology, 52(4), pp. 633-648.
- Longhi, A. et al. (2017) ‘Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society study on 266 patients’, European Journal of Cancer, 74, pp. 9-16.
- Paludo, J. et al. (2018) ‘Extraskeletal osteosarcoma: outcomes and the role of chemotherapy’, American Journal of Clinical Oncology, 41(9), pp. 832-837.
- National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.